Healthcare [ 5/11 ] | Biotechnology [ 54/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 11, 23 | -0.40 Increased by +9.09% | -0.48 Increased by +34.72% |
| Feb 28, 23 | -0.43 Increased by +24.56% | -0.50 Increased by +28.00% |
| Nov 10, 22 | -0.48 Increased by +40.74% | -0.50 Increased by +8.00% |
| Aug 11, 22 | -0.42 Increased by +30.00% | -0.47 Increased by +22.63% |
| May 12, 22 | -0.44 Decreased by -15.79% | -0.58 Increased by +41.62% |
| Mar 15, 22 | -0.57 Decreased by -235.29% | -0.65 Increased by +18.93% |
| Nov 9, 21 | -0.81 Decreased by -50.00% | -0.39 Decreased by -276.13% |
| Aug 10, 21 | -0.60 Increased by +36.17% | -0.50 Decreased by -40.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 21.00 K Decreased by -34.38% | -18.39 M Increased by +5.01% | Decreased by -87.58 K% Decreased by -44.75% |
| Dec 31, 22 | -110.00 K Decreased by -100.00% | -20.23 M Decreased by -111.89% | Increased by +18.39 K% Increased by +476.45 K% |
| Sep 30, 22 | 2.00 K Decreased by -98.73% | -23.52 M Increased by +29.83% | Decreased by -1.18 M% Decreased by -5.43 K% |
| Jun 30, 22 | 8.00 K Decreased by -94.19% | -19.82 M Increased by +20.17% | Decreased by -247.74 K% Decreased by -1.27 K% |
| Mar 31, 22 | 32.00 K Decreased by -96.18% | -19.36 M Decreased by -30.25% | Decreased by -60.50 K% Decreased by -3.31 K% |
| Dec 31, 21 | 4.41 B Increased by +190.55 K% | 170.13 M Increased by +1.70 K% | Increased by +3.86% Increased by +100.84% |
| Sep 30, 21 | 157.56 K Decreased by -94.64% | -33.51 M Decreased by -88.58% | Decreased by -21.27 K% Decreased by -3.42 K% |
| Jun 30, 21 | 137.62 K Decreased by -80.93% | -24.83 M Decreased by -48.07% | Decreased by -18.04 K% Decreased by -676.41% |
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.